Lessons for Specialty Care Payment Reforms: Insights from Maryland’s GBR Model

By HEOR Staff Writer

July 7, 2023

 Maryland’s GBR model has been hailed as a game-changer in tackling the rising costs of healthcare. However, it’s crucial to recognize that payment reforms can have varying effects across different types of care. Here are some key takeaways for CMS’s new value-based specialty care strategy.

1️⃣ Tailored Payment Models: Specialty care savings may require specific payment models for different types of care, like cancer surgery. It’s essential to design reforms that cater to the unique needs of each specialty.

2️⃣ Nuanced Quality Measures: Quality assessment in specialty care should go beyond traditional metrics like readmissions and emergency visits. Patient-reported outcomes and person-centered measures should play a more significant role in evaluating care quality.

3️⃣ Health Equity Considerations: Specialty care reforms must address health equity. By separating reimbursement from volume, vulnerable populations can benefit from sustainable financing. The Global Equity Model offers a framework to assess the success of payment reforms based on health outcomes.

4️⃣ Policy Innovation: Replicating the success of Maryland’s GBR model requires policy innovation and alignment. Other states may need to establish cost growth targets or overcome implementation challenges to ensure viability.

5️⃣ Integration of Primary and Specialty Care: Meaningful delivery system changes are crucial to advancing the integration of primary and specialty care. Global budgets provide a foundation for reorganizing how specialty care is delivered and reimbursed.

There is much to learn from Maryland’s experience and drive effective payment reforms in specialty care. 

 

 

 

Reference url

Recent Posts

MDR software regulations
Impact of MDR Software Regulations on Medical Device Innovation

By João L. Carapinha

May 26, 2026

MDR software regulations under the EU’s Medical Device Regulation (EU 2017/745) are creating heavy operational and financial pressures, according to a survey of 35 SaMD manufacturers listed in the EUDAMED database. Financial burdens hit 88.6 % of respondents at significant or severe levels, while...
GBA-PD therapy development
Key Milestone in GBA-PD Therapy Development Achieved with ACTIVATE Study Completion
Bial announced the completion of the treatment period in its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who carry a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene, referred to as GBA-PD. The 78-week double-blind treatment pha...
CHMP recommendations 2026
CHMP Recommendations 2026: New Approvals and Implications for Health Economics

By HEOR Staff Writer

May 25, 2026

The CHMP recommendations 2026 from the 18–21 May meeting delivered eight positive opinions for new medicines, thirteen extensions of therapeutic indications, and one negative opinion. These decisions bring meaningful progress in areas with significant unmet need, most notably idiopathic pulmonary...